Research and Development Moves the Psychedelics Market Forward
- FN Media Group Presents Microsmallcap.com Market Commentary
NEW YORK, Jan. 27, 2021 /PRNewswire/ The ongoing surge of development and investment into psychedelic medicine and psychedelic-assisted therapy is the direct result of newfound public support and legitimacy for these revolutionary treatments. That legitimacy is being built on the back of a growing body of research showing the benefits of these treatments and the intense need for alternatives to legacy approaches to mental healthcare. The flood of research is continuing, most recently with an
ongoing study on psychosubstances as a potential treatment for veterans with PTSD. As more data supports the legitimacy of these treatments, companies that are commercializing psychedelic medicines, like
Investor Ideas Potcasts #522, Cannabis News and Stocks on the Move (TSX: VLNS) (CSE: HOLL) (CSE: HARV) (CSE: CURA)
Delta, Kelowna, BC - January 25, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
SHARE PODCAST:
Today s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com Potcast featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
Hollister Biosciences Inc. Announces $5 Million Private Placement
January 20, 2021 17:36 ET | Source: Hollister Biosciences Inc. Hollister Biosciences Inc. THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
VANCOUVER, British Columbia, Jan. 20, 2021 (GLOBE NEWSWIRE) Hollister Biosciences Inc. (CSE:HOLL, OTC:HSTRF, FRANKFURT:HOB) (“
Hollister” or the “
Company”) is pleased to announce that it has entered into a letter of engagement with Eight Capital, pursuant to which Eight Capital, acting as sole bookrunner and lead agent, has agreed to offer for sale, together with a syndicate of agents (together with Eight Capital, the “
Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the
Company ,
Hollister Cannabis Co. or
Hollister ) a diversified cannabis branding company with products in over 280 dispensaries throughout California, and over 90 dispensaries throughout Arizona, is pleased to provide an update on its Q4, 2020 performance.
Q4 2020 Update
st, 2020 and ending December 31
st, 2020, Hollister reports that it generated record quarterly revenue of CDN$14.93 million and CDN$2.53 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products. The Company cautions that revenue and EBITDA figures have not yet been audited and are based on reports prepared by management.
In the news release, Hollister Biosciences Inc. Provides Update on Q4 2020 Performance Including CDN $14.93 Million in Revenue With an Estimated CDN $5.53 Million in EBITDA a YoY Revenue Increase of 3215% from Q4 2019, issued 07-Jan-2021 by Hollister Biosciences Inc. over CNW, we are advised by the company that the title should read “CDN $2.53 Million in EBITDA ” rather than “CDN $5.53 Million in EBITDA” as … In the news release, Hollister Biosciences Inc. Provides Update on Q4 2020 Performance Including CDN $14.93 Million in Revenue With an Estimated CDN $5.53 Million in EBITDA a YoY Revenue Increase of 3215% from Q4 2019, issued 07-Jan-2021 by Hollister Biosciences Inc. over CNW, we are advised by the company that the title should read “CDN $2.53 Million in EBITDA ” rather than “CDN $5.53 Million in EBITDA” as originally issued inadvertently. The complete, corrected release follows: